Skip to main content
. 2022 Aug 22;45(10):2360–2368. doi: 10.2337/dc21-2543

Table 1.

Characteristics of participants included in analysis

Characteristic Global (N = 78) Remitters (N = 51) Nonremitters (N = 27) P value*
Distribution
 Age, years 10.4 ± 3.6 10.9 ± 3.4 9.3 ± 4 0.09
 Sex, male, n (%) 41 (52) 30 (59) 10 (37) 0.1
 Pubertal, n (%) 40 (51) 29 (57) 11 (40.7) 0.2
 BMI (z score) −0.7 ± 1.5 −0.6 ± 1.5 −1 ± 1.3 0.3
Baseline diabetes characteristics
 HbA1c, % (mmol/mol) 12.3 (111) ± 2.1 (23) 12.1 (109) ± 2.2 (24) 12.8 (116) ± 1.8 (19) 0.13
 Presence of ketoacidosis, n (%) 26 (33) 13 (26) 13 (48) 0.04
 Glycemia (mg/dL) 475 ± 190 462 ± 197 508 ± 193 0.3
 Weight loss (%) 9.9 ± 15.47 6.9 ± 17.8 15.7 ± 6.8 0.003
Insulin administration
 MDI, n (%) 66 (83.5) 45 (88) 20 (77) 0.3
 Insulin pump, n (%) 9 (11.4) 4 (8) 5 (19) 0.3
 Unknown, n (%) 3 (5) 2 (4) 1 (4) NA
Glycemic control£ (n = 78)
 HbA1c, % (mmol/mol) 6.2 (44) ± 0.7 (8) 6 (42) ± 0.5 (6) 6.7 (50) ± 0.8 (8) 2.5e-20
 Insulin doses (IU/kg/day) 0.6 ± 0.3 0.5 ± 0.2 0.8 ± 0.3 6.1e-20
 IDAA1c 8.5 ± 1.3 7.8 ± 0.8 9.9 ± 1.1 3.4e-38
Fasting and stimulated C-peptide£
 CPEPBASAL (pmol/mL) (n = 73) 0.3 ± 0.2 0.3 ± 0.2 0.2 ± 0.2 0.01
 Peak stimulated (pmol/mL) (n = 52) 0.7 ± 0.4 0.6 ± 0.4 0.4 ± 0.3 0.01
 CPEPSTIM (pmol/mL/min) (n = 52) 0.5 ± 0.3 0.5 ± 0.3 0.4 ± 0.3 0.02
 CPEPEST (pmol/mL)§ (n = 73) 0.6 ± 0.3 0.6 ± 0.2 0.4 ± 0.2 2.6e-06

Data are means ± SD unless otherwise indicated. Percentages may not total to 100 because of rounding.

NA, not applicable.

*

P value calculated between remitters and nonremitters. Results were considered significant when P < 0.05.

Student t test.

χ2.

£

Parameters evaluated at 3 months after diagnosis.

Wilcoxon test.

§

Calculated as described by Wentworth et al. (16).